Briacell Therapeutics Corp (BCTX)

Briacell Therapeutics Corp (BCTX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $30.1M; returns 1 day +0.7%, 1 week +1.0%, 1 year -73.9%.

BriaCell Therapeutics Corp. (BCTX) is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. Their primary focus is on breast cancer immunotherapy, developing off-the-shelf immunotherapy platforms designed to offer personalized treatment. BriaCell's lead candidate, Bria-IMT™, is in a pivotal Phase 3 clinical study for metastatic breast cancer.

Groups BCTX belongs to

• Biotechnology
• Canada Companies
• Clinical Stage Biotech
• Oncology
• Healthcare
• Cancer Therapeutics
• Immunotherapy
• Breast Cancer Treatment
• Clinical Stage
• Life Sciences
• Precision Medicine
• Personalized Medicine
• Biopharmaceutical

BCTX financial model: income statement, cash flow and balance sheet